Glenmark Carvedilol Recall: FDA Cites CGMP Deviations and N-Nitroso Impurity Risk
Glenmark Pharmaceuticals Inc., USA, initiated a Class II recall for Carvedilol Tablets due to CGMP deviations and N-Nitroso Carvedilol I impurity exceeding acceptable limits. This event mandates immediate review of Carvedilol supply chains, highlighting critical regulatory and quality control risks for procurement and regulatory affairs leaders managing cardiovascular drug portfolios.
Glenmark Carvedilol Recall: CGMP Deviations and N-Nitroso Impurity Identified
Glenmark Pharmaceuticals Inc., USA, has initiated a Class II voluntary recall, D-0451-2025, for specific lots of its Carvedilol Tablets USP 25 mg. This critical action, initiated on February 28, 2025, stems from identified Current Good Manufacturing Practice (CGMP) deviations and, more specifically, the presence of 'N-Nitroso Carvedilol I' impurity at levels exceeding the recommended acceptable intake limit. The recalled product, packaged in 500-count bottles under NDC 68462-165-05, was manufactured by Glenmark Pharmaceuticals Ltd. and distributed for Glenmark Pharmaceuticals Inc., USA, based in Mahwah, NJ 07430. A total of 18,696 bottles are affected, covering lots 19231107, 19231114, 19231152 (expiring February 2025), and lot 19234866 (expiring January 2026). This event signals a significant quality control lapse, compelling procurement directors and supply chain VPs to immediately scrutinize their supplier qualification processes and incoming material testing protocols for Carvedilol. The presence of a nitrosamine impurity above acceptable limits is a serious regulatory concern, indicating potential genotoxic risk and demanding swift action to mitigate patient exposure. For regulatory affairs heads, this recall underscores the ongoing industry challenge with nitrosamine formation and the imperative for robust impurity control strategies.
Market Impact and Supply Chain Vulnerability for Carvedilol
The nationwide distribution of Glenmark's recalled Carvedilol Tablets USP 25 mg introduces immediate supply chain vulnerabilities for healthcare providers and distributors across the U.S. Carvedilol, an adrenergic alpha- and beta-antagonist, is a widely prescribed medication for cardiovascular conditions, including hypertension and heart failure. The removal of 18,696 bottles from the market, while not catastrophic for overall supply, can create localized shortages or impact specific formularies heavily reliant on Glenmark as a supplier. Procurement teams must promptly assess their inventory levels and existing contracts to determine their exposure to this specific product and dosage strength. This situation necessitates rapid communication with downstream formulators and pharmacies to manage expectations and prevent potential drug shortages at the patient level. Business development executives should monitor market dynamics closely, as this recall could lead to temporary shifts in market share towards alternative Carvedilol suppliers. The Class II classification, indicating that the product may cause temporary or medically reversible adverse health consequences, further emphasizes the urgency for all stakeholders to ensure uninterrupted access to safe and compliant medication.
Strategic Sourcing: Mitigating Risk and Identifying Alternative Carvedilol Suppliers
In light of Glenmark's Carvedilol recall, procurement directors must prioritize a comprehensive review of their active pharmaceutical ingredient (API) and finished drug product sourcing strategies. The identification of 'N-Nitroso Carvedilol I' impurity underscores the critical need for suppliers with demonstrably robust quality management systems and advanced impurity detection capabilities. While specific alternative suppliers for Carvedilol are not detailed in the available intelligence, best practices dictate diversifying the supplier base to include geographically varied manufacturers. Companies should initiate or accelerate qualification processes for secondary and tertiary suppliers of Carvedilol to ensure supply resilience. This includes evaluating potential suppliers for their history of FDA compliance, their nitrosamine risk assessment protocols, and their ability to meet stringent quality specifications. Regulatory affairs teams should collaborate with procurement to ensure that any new or alternative sources can be qualified swiftly and compliantly, minimizing disruption while upholding patient safety standards. Proactive engagement with contract manufacturers and API providers is essential to understand their current Carvedilol production capacity and regulatory standing.
Regulatory Compliance and Future Outlook for Glenmark Pharmaceuticals
The firm-initiated Class II recall by Glenmark Pharmaceuticals Inc., USA, due to CGMP deviations and impurity issues, places the company under heightened regulatory scrutiny from the FDA. While this is a recall and not a direct Warning Letter, the underlying CGMP deficiencies are precisely the type of issues that often lead to FDA 483 observations and subsequent Warning Letters if not adequately addressed. Regulatory affairs heads should anticipate potential follow-up inspections at the manufacturing site, Glenmark Pharmaceuticals Ltd., to verify corrective and preventive actions (CAPA). The FDA will expect a thorough investigation into the root cause of the N-Nitroso Carvedilol I impurity and the CGMP deviations, along with a robust plan to prevent recurrence. Failure to implement effective CAPA could lead to further enforcement actions, including import alerts or restrictions on future product approvals. Supply chain VPs must factor in these potential regulatory delays and impacts on Glenmark's operational capabilities when forecasting future supply from this vendor. This incident serves as a stark reminder that continuous compliance with CGMP is non-negotiable for market access and sustained operations in the global pharmaceutical landscape.